CRISPR Therapeutics

company in Basel, Switzerland

CRSP Nasdaq ISIN CH0334081137 SEC CIK 1674416 LEI 506700O6IRRIQLT3W370
Follow CRISPR Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $12.7M +1325.1% vs same quarter last year
Net income −$111.4M −4.7% vs same quarter last year
EPS, diluted −$1.15 +1.7% vs same quarter last year
Operating cash flow −$89.7M −6% vs same quarter last year
Revenue by quarter
$35.7M
$865K
$892K
$889K
$864K
$1.5M
$10.2M
$12.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income13 fiscal years
  • Revenue
  • Net income
−$1B−$500M$0$500M$1BFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$3.5M−$581.6M
FY24$37.3M−$366.3M
FY23$371.2M−$153.6M
FY22$1.2M−$650.2M
FY21$915M$377.7M
FY20$719K−$348.9M
FY19$289.6M$66.9M
FY18$3.1M−$165M
FY17$41M−$68.4M
FY16$5.2M−$23.2M
FY15$247K−$25.5M
FY14--
FY13--
MarginsShare of revenue
  • Operating margin
  • Net margin
−60000%−40000%−20000%0%20000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−18933.6%−16569.8%
FY24−1250.4%−981.5%
FY23−60%−41.4%
FY22−56190.4%−54271.7%
FY2140.8%41.3%
FY20−49295.5%−48520.9%
FY1916.1%23.1%
FY18−5087.8%−5281.1%
FY17−157.7%−166.7%
FY16−1319.3%−448.8%
FY15−10416.6%−10325.1%
FY14--
FY13--
Free cash flowOperating cash flow minus capital expenditure
−$750M−$500M−$250M$0$250M$500MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$345.9M
FY24−$144.7M
FY23−$269.8M
FY22−$532.9M
FY21$457.3M
FY20−$256.7M
FY19$50M
FY18−$99M
FY17−$77.9M
FY16−$55.9M
FY15$58.3M
FY14-
FY13-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • CRISPR Therapeutics
  • Healthcare median
−60000%−40000%−20000%0%20000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearCRISPR TherapeuticsHealthcare median
FY25−16569.8%−30.6%
FY24−981.5%−47%
FY23−41.4%−58%
FY22−54271.7%−80.4%
FY2141.3%−71.9%
FY20−48520.9%−62.2%
FY1923.1%−46.3%
FY18−5281.1%−49.6%
FY17−166.7%−45.9%
FY16−448.8%−36%
FY15−10325.1%−38.4%
FY14-−35.5%
FY13-−37.1%